FDA Safe at Home: Looks Inside for Top Safety Official
This article was originally published in RPM Report
Executive Summary
After a tumultuous, two-year hiatus, FDA finally has a permanent director for the Office of Drug Safety. Gerald Dal Pan, MD, succeeded Victor Raczkowski, ending a drawn out serach for what is increasingly becoming a politically sensitive middle management job within FDA.
You may also be interested in...
Coming to Terms with the FDA Commissioner
The Institute of Medicine thinks FDA needs more stability at the highest level, and thinks a six-year fixed term for the commissioner is a good solution. But FDA's new commissioner doesn't agree.
Drug Safety Reform: Did FDA Buy Time or Trouble?
FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.
Drug Safety Reform: Did FDA Buy Time or Trouble?
FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.